View More Recent Stories

Mar 21, 2016 09:18AM IDELVION® for Hemophilia B Now Available in the U.S.
Mar 15, 2016 09:30AM CSL Behring sponsors IDF webinar series for young adults living with primary immunodeficiencies
Mar 9, 2016 09:00AM CSL Behring Awards LEAD Grants to Help Rare Disease Patient Groups Achieve Their Advocacy Objectives
Mar 4, 2016 08:13PM U.S. FDA Approves CSL Behring's IDELVION® -- The First and Only Hemophilia B Therapy with Up to 14-day Dosing Intervals
Feb 23, 2016 09:30AM First Export of Privigen® From New Manufacturing Facility in Broadmeadows, Melbourne, Australia
Feb 10, 2016 10:00AM CSL Plasma Donates Over $225,000 To United Way
Feb 2, 2016 08:00AM CSL Behring and Its Employees Pass $1 Million Mark in Charitable Donations to Communities Throughout the U.S.
Dec 22, 2015 09:00AM CSL Behring Submits Marketing Authorization Application to the European Medicines Agency for rVIII-SingleChain for Patients with Hemophilia A
Dec 21, 2015 09:01AM CSL Behring Submits New Drug Application to Japan's Pharmaceuticals and Medical Devices Agency for rIX-FP for Hemophilia B Patients
Dec 7, 2015 11:00AM CSL Behring Presents Phase III Data for Its Long-Acting Recombinant Factor IX Albumin Fusion Protein for Hemophilia B at the 57th ASH Annual Meeting & Exposition
Dec 2, 2015 09:00AM CSL Behring to Present New Data for rIX-FP and rVIII-SingleChain at the 57th ASH Annual Meeting & Exposition
Apr 1, 2015 01:24PM Graco Completes Divestiture of Liquid Finishing Business Assets
Mar 25, 2015 01:40PM Graco Receives Approval from FTC to Sell Liquid Finishing Business Assets
Feb 4, 2015 03:50PM Trading Radar for 2/4: Twitter (TWTR), GoPro (GPRO), LinkedIn (LNKD), Kors (KORS), Philip Morris (PM) Report
View More Recent Stories